Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000902664-26-001046·C4 Therapeutics, Inc.
Schedule 13G ownership disclosure
C4 Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 12529R107
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Lynx1 Capital Management LP
Shares: 7,098,133.00 · Class: 7.3%
- Weston Nichols
Shares: 7,098,133.00 · Class: 7.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-26-001046
- Form type
- SCHEDULE 13G/A
- Filer
- C4 Therapeutics, Inc.
- CIK
- CIK 1662579
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership